At ERBC, we offer comprehensive Oncology Efficacy Studies utilizing a variety of orthotopic and heterotopic murine tumor models, including glioblastoma, colorectal, pancreatic, ovarian, and myeloma models, to evaluate the therapeutic potential of cancer treatments. Our models are highly relevant, representing murine (syngeneic) or human (xenografted) tumor biology and providing critical data on tumor progression, metastasis, and therapeutic responses.
In addition to traditional tumor models, we also specialize in the use of our AVI-cellDX and AVI-PDX™ model, developed with avian embryos, which allows for rapid and reliable testing of oncology treatments in a patient-derived xenograft (PDX) format. This model enables real-time tracking of tumor formation and drug efficacy, offering a unique advantage for early-stage drug development.
To track tumor growth and treatment efficacy, we utilize non-invasive in vivo imaging technologies, including bioluminescence, CT, and micro-CT, which allow longitudinal monitoring of tumors, reducing animal use and improving accuracy. These technologies also enable us to assess compound biodistribution in real-time, providing valuable insights into how a drug is distributed in the body and whether it targets the tumor tissue effectively.
Our team is also experienced in the development of immuno-oncology therapies, offering high-technology inflammatory readouts such as flow cytometry, luminex, and RT-qPCR analysis to evaluate the immune response, biodistribution, and potential adverse effects in cancer therapies. With a strong background in evaluating CAR-T cells and other novel immunotherapies, we provide comprehensive solutions to assess both tumor growth and immune system interactions in oncology.
